Edwards Lifesciences Receivables

Edwards Lifesciences (EW) currently reports a receivables of $960M as of June 2026. That compares with $900M in the prior-year period — up 5.9% year over year. Use the charts on this page to explore Edwards Lifesciences's receivables history and peer comparisons.

Edwards Lifesciences's receivables increased from $900M to $960M — a 5.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Edwards Lifesciences reported $960M in receivables as of June 2026. That compares with $900M in the prior-year period — up 5.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $960M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Edwards Lifesciences, and consider following EW for alerts when major investors trade the stock.

Edwards Lifesciences is classified in the Healthcare sector. On receivables, it currently shows $960M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EW with unrelated industries.